We Are Crinetics
Crinetics is a pharmaceutical company that researches, discovers, and develops breakthrough therapies for patients with
rare endocrine diseases or tumors. We foster long-term relationships with healthcare practitioners to learn intimately
about the challenges patients face every day, then focus on developing game-changing therapies that improve their lives
in significant ways.
NANETS 2022 POSTER PRESENTATION
A Phase 2, Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.
Presented by:
Aman Chauhan, M.D., study co-author
Director of NET Theranostics UK Markey Cancer CenterUniversity of Kentucky Healthcare
Friday, October 28, 5:15-7:00PM in The Poster Hall
CONTACT US
Please fill out the information below and our medical affairs team will reach out to you about Crinetics and our Phase 2 and future Phase 3 studies with paltusotine for the treatment of carcinoid syndrome.
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|